J&J’s Blockbuster Tremfya Flops in Phase II Giant Cell Arteritis Trial

Johnson & Johnson is halting a mid-stage trial investigating its monoclonal antibody Tremfya (guselkumab) in giant cell arteritis after it failed to reach the primary endpoint.